



## Investor Update - Conference Call



May 2012

# Cash Position

---

- Appendix 4C released
- Cash at the end of March \$1211K
- Expenses coming down... \$329K for March v \$890K average for YTD
- Tax rebate expected by Dec Q
- Line of credit of \$1M identified subject to tax rebate calcs and docs
- Thus it is estimated there will be cash available with Tax rebate into Dec Q

# Management Action

since last conference call

---

- President and CEO visited Potential buyers of the business
- Described plans to demonstrate CXD business model in the UK
- Described the patent and skills portfolio and discussed the potential fit with buyers
- Obtained verbal indications of interest

# Management Action

since last conference call

---

- 6 Doctor trials with loop diagnostic device completed successfully
- Prelim discussions on regulatory plans completed successfully with Notified Body
- Manufacturing equipment has been packed and is on the way to Malaysia

## Capitalisation Matters

---

- Market cap is approx \$4M
- Rights issue underwriting negotiations have begun
- Underwriting terms would likely include a requirement for CathRx to delist.
- Current plan is to seek shareholder approval to delist CathRx after the capital raising
- Delisting does not affect the operations of CathRx. The public company structure would remain.
- But primary exit from the stock will be by sale of the business not trading on the ASX

---

Please review the CathRx web site  
for further information:  
[www.cathrx.com](http://www.cathrx.com)

I will now move to  
questions

